University of Tasmania

File(s) under permanent embargo

EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography

journal contribution
posted on 2023-05-18, 00:54 authored by Lang, RM, Badano, LP, Tsang, W, Adams, DH, Agricola, E, Buck, T, Faletra, FF, Franke, A, Hung, J, Perez de Isla, L, Kamp, O, Kasprzak, JD, Lancellotti, P, Thomas MarwickThomas Marwick, McCulloch, ML, Monaghan, MJ, Nihoyannopoulos, P, Pandian, NG, Pellikka, PA, Pepi, M, Roberson, DA, Shernan, SK, Shirali, GS, Sugeng, L, Ten Cate, FJ, Vannan, MA, Zamorano, JL, Zoghbi, WA
Context Current guidelines recommend the use of aldosterone antagonists (AA) in patients with moderately severe to severe symptoms [New York Heart Association (NYHA) class III to IV] and systolic heart failure.
Objective To determine the efficacy of AA in improving ejection fraction (EF) and functional capacity and to assess whether this effect was influenced by baseline NYHA classification.
Study design Meta-analysis of randomized controlled trials. Data extraction performed independently by two researchers.
Data Sources MEDLINE and the Cochrane Library.
Study Selection Prospective randomized controlled trials using AA were included if there was a clear description of the baseline NYHA classification and change in EF in patients from study initiation to completion.
Results Data from 1,575 patients enrolled in fourteen studies were included. Overall, there was a weighted mean improvement in EF of 3.2% and in NYHA classification of 0.13 in subjects treated with AA when compared to controls (p<0.001). A mixed effects meta-regression analysis revealed that baseline NYHA was not predictive of improvement in EF (p=0.67) nor NYHA status (p=0.18).
Conclusions The results of this meta-analysis suggest that AA is associated with significant improvements in EF and functional class independent of baseline functional capacity. This supports and expands on the recently published EMPHASIS-HF trial and suggests that the current restriction of AA use to patients with NYHA class III-IV symptoms should be reconsidered.


Publication title

European Heart Journal








Menzies Institute for Medical Research


W B Saunders Co Ltd

Place of publication

32 Jamestown Rd, London, England, Nw1 7By

Rights statement

Copyright 2012 Oxford University Press

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania


    Ref. manager